Orchid Pharma Limited – Investor Presentation Summary

Key Operational Highlights

  • EXBLIFEP positioned as India's only novel antibiotic and only USFDA-approved sterile cephalosporin
  • Built on 30 years of cephalosporin expertise with expansion into AMR and regulated markets
  • Two entities merged into one Orchid: Dhanuka Laboratories Ltd. amalgamated into Orchid Pharma Ltd. effective April 1, 2024 under NCLT-sanctioned Scheme

Key drivers of operational performance: EXBLIFEP business development through licensing partnerships

Segment-wise Performance

Not Specified

Financial Highlights

Revenue: ₹341.27 Cr (Q2 FY27), ₹645.44 Cr (H1 FY27)

EBITDA: ₹52 Cr (Q2 FY27), ₹77 Cr (H1 FY27)

PAT: ₹36.76 Cr (Q2 FY27), ₹48.70 Cr (H1 FY27)

EPS: ₹6.14 (Q2 FY27), ₹8.13 (H1 FY27)

Margins: EBITDA Margin 15% (Q2 FY27), 12% (H1 FY27)

YoY/QoQ comparison: Q2 FY27 revenue +14% YoY, EBITDA +148% YoY; H1 FY27 revenue +15% YoY, EBITDA +151% YoY

Drivers of financial performance: Revenue growth, operational efficiencies

Comparison to market estimates: Not Specified

Key Risks: Not Specified

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Debt/Equity ratio 0.33x (Consolidated, Sep 2026)

Reserves: Other equity ₹1,633.14 Cr (Standalone, Sep 2026)

Current Assets/Liabilities: Current assets ₹877.95 Cr, Current liabilities ₹550.60 Cr (Standalone, Sep 2026)

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Total assets increased to ₹2,652 Cr from ₹2,258 Cr (Mar 2026)

Capex & Cash Flow Health

Capital Expenditure: Capital work-in-progress ₹196.12 Cr (Standalone, Sep 2026), Intangibles under development ₹15.85 Cr (Standalone, Sep 2026)

Free Cash Flow: Not Specified

Operating Cash Flow: Net cash from operating activities ₹90.71 Cr (Standalone H1 FY27), ₹117.78 Cr (Consolidated H1 FY27)

Net Debt Movement: Gross borrowings increased to ₹544 Cr from ₹301 Cr (Mar 2026)

Investment Rationale: Capacity expansion and intangible development

Strategic & R&D Initiatives

Investments in Innovation: EXBLIFEP - India's only novel antibiotic platform

Expected impact on growth: Licensing partnerships estimated at $80M sales potential

Strategic Rationale: Expanding into AMR and regulated markets through partnerships

Industry Trends & Business Environment

Macro/Industry Trends: Antimicrobial Resistance (AMR) focus

Impact on Company: Positioning as integrated anti-infective platform globally

Management Commentary & Growth Outlook

Strategic Outlook: Not Specified

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified